Follow Us:
Lamivudine Exporter From India

Lamivudine

Lamivudine is an antiviral medication used to treat human immunodeficiency virus (HIV-1) infection in combination with other antiretroviral medicines and chronic hepatitis B infection. It belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and works by inhibiting viral reverse transcriptase or hepatitis B virus DNA polymerase, reducing viral replication. It is available as oral tablets, dispersible tablets, and oral solution. Common side effects include headache, nausea, fatigue, diarrhoea, and cough. Important precautions include monitoring liver function, kidney function, and the risk of lactic acidosis or severe hepatomegaly with steatosis. Lamivudine should be used under medical supervision, and treatment for HIV or hepatitis B should not be discontinued without medical advice.

  • Dosage Form:
  • Dosage Strength:
  • Manufacturer:
  • CAS No.:
  • Status:

Applications of Lamivudine

Lamivudine was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

is okay

Contraindication of Lamivudine

Availability of Lamivudine

Delivery of Lamivudine

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Lamivudine.

The is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Lamivudine.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Lamivudine, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Lamivudine Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Lamivudine

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Lamivudine Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Lamivudine, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Lamivudine

The export of Lamivudine from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Lamivudine Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Lamivudine specifications, certificates of analysis, and other supporting documents required for Lamivudine export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Lamivudine export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Lamivudine regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Lamivudine documentation, labelling, Lamivudine manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Lamivudine Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Lamivudine, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.